Allergic rhinitis in children: Selecting an intranasal corticosteroid

Pediatric Asthma, Allergy and Immunology

Volumn 18, Issue 4, 2005, Pages 216-229

  Murphy, Kevin R ^a  

^a Midwest Allergy and Asthma Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; BENZALKONIUM CHLORIDE; BUDESONIDE; CARBOXYMETHYLCELLULOSE; CITRIC ACID; CORTICOSTEROID; EDETATE DISODIUM; EXCIPIENT; FLUTICASONE PROPIONATE; GLUCOSE; GLYCEROL; MICROCRYSTALLINE CELLULOSE; MOMETASONE FUROATE; PHENETHYL ALCOHOL; PLACEBO; POLYSORBATE 80; SORBATE POTASSIUM; TRIAMCINOLONE ACETONIDE;

ADRENAL FUNCTION; ALLERGIC RHINITIS; CHILD; CHILD GROWTH; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GROWTH RATE; HUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STEROID THERAPY;

EID: 29144484683     PISSN: 08831874     EISSN: None     Source Type: Journal    
DOI: 10.1089/pai.2005.18.216     Document Type: Review

References (59)

1. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(5 Suppl):S147-334.
2. Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J, Li JT, Bernstein IL, Berger W, Spector S, Schuller D. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81(5 Pt 2):478-518.
3. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001; 108(1 Suppl):S45-53.
4. Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997; 99:S773-780.
5. Reissman D, Price T, Leibman CW. Cost efficiency of intranasal corticosteroid prescribing patterns in the management of allergic rhinitis. J Manag Care Pharm 2004; 10(1 Suppl):S9-13.
6. van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR, Fokkens WJ, Howarth PH, Lund V, Malling H-J, Mygind N, Passali D, Scadding GK, Wang D-Y. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55:116-134.
7. Storms WW. Rethinking our approach to allergic rhinitis management. Ann Allergy Asthma Immunol 2002; 88(4 Suppl 1):30-35.
8. Nathan RA. Pharmacotherapy for allergic rhinitis: A critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma Immunol 2003; 90:182-190.
9. Nielsen LP, Mygind N, Dahl R. Intranasal corticosteroids for allergic rhinitis: Superior relief? Drugs 2001; 61:1563-1579.
10. 1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 1998; 317:1624-1629.
11. 1 receptor antagonists for the treatment of allergic rhinitis: A systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002; 89:479-484.
12. Viner AS, Jackman N. Retrospective survey of 1271 patients diagnosed as perennial rhinitis. Clin Allergy 1976; 6:251-259.
13. Durham SR. The inflammatory nature of allergic disease. Clin Exp Allergy 1998; 28(Suppl 6):20-24.
14. Naclerio R, Solomon W. Rhinitis and inhalant allergens. JAMA 1997; 278:1842-1848.
15. Nathan RA. Changing strategies in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 1996; 77:255-259.
16. Lieberman PL, Settipane RA. Azelastine nasal spray: A review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis. Allergy Asthma Proc 2003; 24:95-105.
17. Stern MA, Wade AG, Ridout SM, Cambell LM. Nasal budesonide offers superior symptom relief in perennial allergic rhinitis in comparison to nasal azelastine. Ann Allergy Asthma Immunol 1998; 81:354-358.
18. Dupclay L, Doyle J. Assessment of intranasal corticosteroid use in allergic rhinitis: Benefits, costs, and patient preferences. Am J Manag Care 2002; 8(13 Suppl):S335-340.
19. Fokkens WJ, Cserháti E, dos Santos JML, Praca F, van Zanten M, Schade A, Simon G. Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. Ann Allergy Asthma Immunol 2002; 89:279-284.
20. Day J, Alexander M, Drouin M, Frankish C, Mazza J, Moote W, Patel P, Ramsdale H, Yang W. Budesonide aqueous nasal spray and pressurized metered dose inhaler in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol 1997; 11:77-83.
21. Creticos P, Fireman P, Settipane G, Bernstein D, Casale T, Schwartz H. Intranasal budesonide aqueous pump spray (Rhinocort Aqua) for the treatment of seasonal allergic rhinitis. Rhinocort Aqua Study Group. Allergy Asthma Proc 1998; 19:285-294.
22. Meltzer EO. Clinical and anti-inflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 1998; 81:128-134.
23. Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group. Ann Allergy Asthma Immunol 1997; 79:370-378.
24. Drouin M, Yang WH, Bertrand B, Van Cauwenberg P, Clement P, Dalby K, Darnell R, Ernst T-M, Hebert J, Karlsson G, Luciuk G, Mazza J, Roovers M, Ruoppi P, Seppey M, Stern M, Suonpää J, Sussman G, Tan KY, Tse K, Widjaja P, Jensen P, Nolop K, Lutsky BN. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996; 77:153-160.
25. Storms W, Bronsky E, Findlay S, Pearlman D, Rosenberg S, Shapiro G, Southern L, Tinkelman D, Weakley S, Welch M, et al. Once daily triamcinolone acetonide nasal spray is effective for the treatment of perennial allergic rhinitis. Ann Allergy 1991; 66:329-334.
26. Gawchik S, Goldstein S, Prenner B, John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 2003; 90:416-421.
27. Nielsen LP, Dahl R. Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: A review of randomized, controlled trials. Am J Respir Med 2003; 2:55-65.
28. Gross G, Jacobs RL, Woodworth TH, Georges GC, Lim JC. Comparative efficacy, safety, and effect on quality of life of triamcinolone acetonide and fluticasone propionate aqueous nasal sprays in patients with fall seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89:56-62.
29. Berger WE, Kaiser H, Gawchik SM, Tillinghast J, Woodworth TH, Dupclay L, Georges GC. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. Otolaryngol Head Neck Surg 2003; 129:16-23.
30. Kaiser HB, Liao Y, Diener P, Leahy MJ, Garcia J, Georges G. Triamcinolone acetonide and fluticasone propionate nasal sprays provide comparable relief of seasonal allergic rhinitis symptoms regardless of disease severity. Allergy Asthma Proc 2004; 25:423-428.
31. Ahlström-Emanuelsson C, Persson CG, Svensson C, Andersson M, Hosszu Z, Akerlund A, Greiff L. Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid. Ann Allergy Asthma Immunol 2002; 89:159-165.
32. Stern MA, Dahl R, Nielsen LP, Pedersen B, Schrewelius C. A comparison of aqueous suspensions of budesonide nasal spray (128 micrograms and 256 micrograms once daily) and fluticasone propionate nasal spray (200 micrograms once daily) in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol 1997; 11:323-330.
33. Day J, Carrillo T. Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis. J Allergy Clin Immunol 1998; 102(6 Pt 1):902-908.
34. Bende M, Carrillo T, Vóna I, da Castel-Branco MG, Arheden L. A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann Allergy Asthma Immunol 2002; 88:617-623.
35. Day JH, Briscoe MP, Rafeiro E, Ellis AK, Pettersson E, Akerlund A. Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model. J Allergy Clin Immunol 2000; 105:489-494.
36. Berkowitz RB, Bernstein DI, LaForce C, Pedinoff AJ, Rooklin AR, Damaraju CRV, Mesarina-Wicki B, Nolop KB. Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy 1999; 54:64-69.
37. Berkowitz RB, Roberson S, Zora J, Capano D, Chen R, Lutz C, Harris AG. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 1999; 20:167-172.
38. Munk ZM, LaForce C, Furst JA, Simpson B, Feiss G, Smith JA. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996; 77:277-281.
39. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 1999; 104:948-952.
40. Skoner DP, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003; 90:56-62.
41. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997; 19:1330-1339.
42. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, Rosen JP, Ruff ME, Vandewalker ML, Wanderer A, Damaraju CV, Nolop KB, Mesarina-Wicki B. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105:E22.
43. Galant SP, Melamed IR, Nayak AS, Blake KV, Prillaman BA, Reed KD, Cook CK, Philpot EE, Rickard KA. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics 2003; 112(1 Pt 1):96-100.
44. Nayak AS, Ellis MH, Gross GN, Mendelson LM, Schenkel EJ, Lanier BQ, Simpson B, Mullin ME, Smith JA. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol 1998; 101(2 Pt 1):157-162.
45. Kim KT, Rabinovitch N, Uryniak T, Simpson B, O'Dowd L, Casty F. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol 2004; 93:61-67.
46. United States Department of Health and Human Services, Food and Drug Administration. Evaluation of the effects of orally inhaled and intranasal corticosteroids on growth in children: a guidance for industry. November 2001. www.fda.gov/cder/guidance/3787dft.pdf (Last accessed on March 8, 2005).
47. Allen DB, Meltzer EO, Lemanske RF, Philpot EE, Faris MA, Kral KM, Prillaman BA, Rickard KA. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002; 23:407-413.
48. Murphy K, Uryniak T, Simpson B, O'Dowd L. Growth velocity is not suppressed in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray 64 μg once daily for 1 year. Ann Allergy Asthma Immunol (in press).
49. Möller C, Lars E, Svensson IL. Nasal budesonide to children for 5 years [Abstract 1546]. Allergy Clin Immunol News 1994; Suppl 2:427.
50. Möller C, Ahlstrom H, Henricson KA, Malmqvist LA, Akerlund A, Hildebrand H. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 2003; 33:816-822.
51. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, Storms WW, Wood RA. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000; 105:E23.
52. Juniper EF, Ståhl E, Doty RL, Simons FER, Allen DB, Howarth PH. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol 2005; 115:S390-S413.
53. Gerson I, Green L, Fishken D. Patient preference and sensory comparisons of nasal spray allergy medications. J Sensory Studies 1999; 14:491-496.
54. Bachert C, El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89:292-297.
55. Stokes M, Amorosi SL, Thompson D, Dupclay L, Garcia J, Georges G. Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg 2004; 131:225-231.
56. Shah SR, Miller C, Pethick N, Uryniak T, Jones MK, O'Dowd L. Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray. Clin Ther 2003; 25:2198-2214.
57. Bernstein IL. Is the use of benzalkonium chloride as a preservative for nasal formulations a safety concern? A cautionary note based on compromised mucociliary transport. J Allergy Clin Immunol 2000; 105(1 Pt 1):39-44.
58. Lennox RD, Fowler I, Gore M, Jones MK, Pethick N, O'Dowd L. Psychometric validation of a patient-reported sensory perception and preference instrument: The Sensory Perceptions Questionnaire. Adv Ther 2004; 21:162-172.
59. Mahadevia PJ, Shah SR, Leibman C, Kleinman L, O'Dowd L. Patient preference for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy in allergic rhinitis: A conjoint analysis. Ann Allergy Asthma Immunol 2004; 93:345-350.